Table 4

Responses on the Taxol/CP/5-FU regimen

Cancer typesResponses/evaluable patient/total no. of patientsSites of response
Breast6 (2 CRs)/8/11Chest wall, lymph nodes, lung
Head and neck cancer2/3/6Neck lymph node mass
NSCLCa3/6/8Liver and hilar adenopathy, lung
Esophagus8 (3 CRs)/8/9Epidermoid, adenocarcinomas
Melanoma1/2/2Lung metastasis
SCLC2/2/2Head of pancreas mass
Total22 (5 CRs)/32/42
  • a NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer.